Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1964 2
1970 1
1972 1
1975 4
1977 6
1978 6
1979 3
1980 2
1981 12
1982 13
1983 8
1984 12
1985 7
1986 11
1987 6
1988 5
1989 5
1990 11
1991 6
1992 10
1993 8
1994 12
1995 17
1996 8
1997 2
1998 3
1999 5
2000 2
2001 5
2002 13
2003 6
2004 10
2005 6
2006 3
2007 13
2008 7
2009 20
2010 17
2011 23
2012 24
2013 27
2014 21
2015 36
2016 41
2017 33
2018 49
2019 47
2020 34
2021 47
2022 36
2023 22
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

663 results

Results by year

Filters applied: . Clear all
Page 1
Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.
Dubourg J, Fouqueray P, Quinslot D, Grouin JM, Kaku K. Dubourg J, et al. Among authors: kaku k. Diabetes Obes Metab. 2022 Apr;24(4):609-619. doi: 10.1111/dom.14613. Epub 2021 Dec 27. Diabetes Obes Metab. 2022. PMID: 34866306 Free PMC article. Clinical Trial.
[Alogliptin].
Tanabe A, Kaku K. Tanabe A, et al. Among authors: kaku k. Nihon Rinsho. 2011 May;69(5):871-6. Nihon Rinsho. 2011. PMID: 21595274 Review. Japanese.
Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).
Kimura T, Katakura Y, Shimoda M, Kawasaki F, Yamabe M, Tatsumi F, Matsuki M, Iwamoto Y, Anno T, Fushimi Y, Kamei S, Kimura Y, Nakanishi S, Mune T, Kaku K, Kaneto H; COMING study Group. Kimura T, et al. Among authors: kaku k. Diabetes Obes Metab. 2023 Dec;25(12):3632-3647. doi: 10.1111/dom.15258. Epub 2023 Aug 30. Diabetes Obes Metab. 2023. PMID: 37646192 Clinical Trial.
Global trends in satellite-based emergency mapping.
Voigt S, Giulio-Tonolo F, Lyons J, Kučera J, Jones B, Schneiderhan T, Platzeck G, Kaku K, Hazarika MK, Czaran L, Li S, Pedersen W, James GK, Proy C, Muthike DM, Bequignon J, Guha-Sapir D. Voigt S, et al. Among authors: kaku k. Science. 2016 Jul 15;353(6296):247-52. doi: 10.1126/science.aad8728. Science. 2016. PMID: 27418503 Review.
Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study.
Katakura Y, Shimoda M, Ohnishi M, Kusano T, Dan K, Isobe H, Wamata R, Iwamoto Y, Fushimi Y, Sanada J, Obata A, Kimura T, Tatsumi F, Nakanishi S, Mune T, Kaku K, Kaneto H. Katakura Y, et al. Among authors: kaku k. Nutr Metab Cardiovasc Dis. 2023 Jul;33(7):1444-1452. doi: 10.1016/j.numecd.2023.02.011. Epub 2023 Feb 21. Nutr Metab Cardiovasc Dis. 2023. PMID: 37246074 Free article.
Efficacy of voglibose in type 2 diabetes.
Kaku K. Kaku K. Expert Opin Pharmacother. 2014 Jun;15(8):1181-90. doi: 10.1517/14656566.2014.918956. Epub 2014 May 5. Expert Opin Pharmacother. 2014. PMID: 24798092 Review.
663 results